Nurix Therapeutics (Nurix Therapeutics) 3-Year Book Growth Rate : -18.00% (As of Feb. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Nurix Therapeutics 3-Year Book Growth Rate?

Nurix Therapeutics's Book Value per Share for the quarter that ended in Feb. 2024 was $3.43.

During the past 12 months, Nurix Therapeutics's average Book Value per Share Growth Rate was -40.50% per year. During the past 3 years, the average Book Value per Share Growth Rate was -18.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 6 years, the highest 3-Year average Book Value per Share Growth Rate of Nurix Therapeutics was -18.00% per year. The lowest was -18.00% per year. And the median was -18.00% per year.

Competitive Comparison of Nurix Therapeutics's 3-Year Book Growth Rate

For the Biotechnology subindustry, Nurix Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nurix Therapeutics's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nurix Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Nurix Therapeutics's 3-Year Book Growth Rate falls into.

Nurix Therapeutics 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Nurix Therapeutics (NAS:NRIX) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Nurix Therapeutics 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Nurix Therapeutics's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Nurix Therapeutics (Nurix Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nurix Therapeutics Inc (NAS:NRIX) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

1700 Owens Street, Suite 205, San Francisco, CA, USA, 94158

Website

http://www.nurixtx.com

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

Executives

Houte Hans Van	officer: Chief Financial Officer	C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Christine Ring	officer: General Counsel	C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Gwenn Hansen	officer: Chief Scientific Officer	C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Stefani Wolff	officer: EVP and COO	C/O PRINCIPIA BIOPHARMA INC., 400 EAST JAMIE COURT, SUITE 302, SOUTH SAN FRANCISCO CA 94080
Edward C Saltzman	director	C/O NURIX THERAPEUTICS, 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Paul M Silva	director	C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST, CAMBRIDGE MA 02139
Judith A Reinsdorf	director	C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Pierre Beaurang	officer: Chief Business Officer	C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158
Clay B Siegall	director	21823 30TH DR SE, BOTHELL WA 98021
Ponoi Capital, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Ii Management, Llc	10 percent owner	1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Ponoi Capital Ii, Lp	10 percent owner	1700 OWENS STREET, STE 500, SAN FRANCISCO CA 94158
Column Group Gp, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group L P	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Management, Llc	10 percent owner	1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129